Literature DB >> 30731481

Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm Delivery.

Michael W Varner1, Maged M Costantine2, Kathleen A Jablonski3, Dwight J Rouse4, Brian M Mercer5, Kenneth J Leveno6, Uma M Reddy7, Catalin Buhimschi8, Ronald J Wapner9,10, Yoram Sorokin11, John M Thorp12, Susan M Ramin13, Fergal D Malone14, Marshall Carpenter15, Mary J O'sullivan16, Alan M Peaceman17, Donald J Dudley18, Steve N Caritis19.   

Abstract

OBJECTIVE: To evaluate sex-specific genetic susceptibility to adverse neurodevelopmental outcome (ANO, defined as cerebral palsy [CP], mental, or psychomotor delay) at risk for early preterm birth (EPTB, < 32 weeks). STUDY
DESIGN: Secondary case-control analysis of a trial of magnesium sulfate (MgSO4) before anticipated EPTB for CP prevention. Cases are infants who died by the age of 1 year or developed ANO. Controls, matched by maternal race and infant sex, were neurodevelopmentally normal survivors. Neonatal DNA was evaluated for 80 polymorphisms in inflammation, coagulation, vasoregulation, excitotoxicity, and oxidative stress pathways using Taqman assays. The primary outcome for this analysis was sex-specific ANO susceptibility. Conditional logistic regression estimated each polymorphism's odds ratio (OR) by sex stratum, adjusting for gestational age, maternal education, and MgSO4-corticosteroid exposures. Holm-Bonferroni corrections, adjusting for multiple comparisons (p < 7.3 × 10-4), accounted for linkage disequilibrium between markers.
RESULTS: Analysis included 211 cases (134 males; 77 females) and 213 controls (130 males; 83 females). An interleukin-6 (IL6) polymorphism (rs2069840) was associated with ANO in females (OR: 2.6, 95% confidence interval [CI]: 1.5-4.7; p = 0.001), but not in males (OR: 0.8, 95% CI: 0.5-1.2; p = 0.33). The sex-specific effect difference was significant (p = 7.0 × 10-4) and was unaffected by MgSO4 exposure. No other gene-sex associations were significant.
CONCLUSION: An IL6 gene locus may confer susceptibility to ANO in females, but not males, after EPTB. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30731481      PMCID: PMC6685763          DOI: 10.1055/s-0039-1678535

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  34 in total

1.  Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway.

Authors:  Lina Du; Hülya Bayir; Yichen Lai; Xiaopeng Zhang; Patrick M Kochanek; Simon C Watkins; Steven H Graham; Robert S B Clark
Journal:  J Biol Chem       Date:  2004-07-01       Impact factor: 5.157

2.  Sex differences in cell death.

Authors:  Hong Li; Scott Pin; Zhiyuan Zeng; Michael M Wang; Katrin A Andreasson; Louise D McCullough
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

3.  The fetal inflammatory response syndrome.

Authors:  R Gomez; R Romero; F Ghezzi; B H Yoon; M Mazor; S M Berry
Journal:  Am J Obstet Gynecol       Date:  1998-07       Impact factor: 8.661

4.  Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth.

Authors:  Erin A S Clark; Steven J Weiner; Dwight J Rouse; Brian M Mercer; Uma M Reddy; Jay D Iams; Ronald J Wapner; Yoram Sorokin; Fergal D Malone; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald J Dudley; Steve N Caritis
Journal:  Am J Perinatol       Date:  2018-03-06       Impact factor: 1.862

5.  Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children.

Authors:  Pål Surén; Inger Johanne Bakken; Heidi Aase; Richard Chin; Nina Gunnes; Kari Kveim Lie; Per Magnus; Ted Reichborn-Kjennerud; Synnve Schjølberg; Anne-Siri Øyen; Camilla Stoltenberg
Journal:  Pediatrics       Date:  2012-06-18       Impact factor: 7.124

6.  The association of genetic polymorphisms with cerebral palsy: a meta-analysis.

Authors:  De Wu; Yan-Feng Zou; Xiao-Yan Xu; Xiao-Liang Feng; Li Yang; Gong-Chun Zhang; Xi-Song Bu; Jiu-Lai Tang
Journal:  Dev Med Child Neurol       Date:  2011-03       Impact factor: 5.449

7.  Repeated course antenatal steroids, inflammation gene polymorphisms, and neurodevelopmental outcomes at age 2.

Authors:  Erin A S Clark; Lisa Mele; Ronald J Wapner; Catherine Y Spong; Yoram Sorokin; Alan Peaceman; Jay D Iams; Kenneth J Leveno; Margaret Harper; Steve N Caritis; Brian M Mercer; John M Thorp; Susan M Ramin; Marshall Carpenter; Dwight J Rouse
Journal:  Am J Obstet Gynecol       Date:  2011-02-27       Impact factor: 8.661

8.  Claims of sex differences: an empirical assessment in genetic associations.

Authors:  Nikolaos A Patsopoulos; Athina Tatsioni; John P A Ioannidis
Journal:  JAMA       Date:  2007-08-22       Impact factor: 56.272

9.  Association of polymorphisms in neuroprotection and oxidative stress genes and neurodevelopmental outcomes after preterm birth.

Authors:  Maged M Costantine; Erin A S Clark; Yinglei Lai; Dwight J Rouse; Catherine Y Spong; Brian M Mercer; Yoram Sorokin; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall Carpenter; Menachem Miodovnik; Mary J O'Sullivan; Alan M Peaceman; Steve N Caritis
Journal:  Obstet Gynecol       Date:  2012-09       Impact factor: 7.661

10.  Neurologic and developmental disability at six years of age after extremely preterm birth.

Authors:  Neil Marlow; Dieter Wolke; Melanie A Bracewell; Muthanna Samara
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

View more
  2 in total

1.  Early Inflammatory Measures and Neurodevelopmental Outcomes in Preterm Infants.

Authors:  Marliese Dion Nist; Abigail B Shoben; Rita H Pickler
Journal:  Nurs Res       Date:  2020 Sep/Oct       Impact factor: 2.381

Review 2.  Do preterm girls need different nutrition to preterm boys? Sex-specific nutrition for the preterm infant.

Authors:  Anna C Tottman; Colleen J Oliver; Jane M Alsweiler; Barbara E Cormack
Journal:  Pediatr Res       Date:  2020-11-12       Impact factor: 3.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.